Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 1/2021

Open Access 01-02-2021 | Erythema | Review

Rosacea Treatment: Review and Update

Authors: Hanlin Zhang, Keyun Tang, Yuchen Wang, Rouyu Fang, Qiuning Sun

Published in: Dermatology and Therapy | Issue 1/2021

Login to get access

Abstract

Rosacea is a chronic and inflammatory skin disease characterized by flushing, nontransient erythema, papules/pustules, telangiectasia, and phymatous changes. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea. In 2017, a phenotype-based approach for diagnosis and classification was recommended. With the update of the diagnosis and classification of rosacea, treatment options for patients with rosacea have attracted the attention of dermatologists. Here, we summarize the latest advances in rosacea treatment, including skin care and cosmetic treatments, topical therapies, oral therapies, laser- and light-based therapies, injection therapies, treatments for specific types of rosacea, treatments for systemic comorbidities, and combination therapies. The impact of the phenotype-based approach on rosacea treatment and future directions are also discussed.
Literature
1.
2.
Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):431–8.PubMed
3.
Dursun R, Daye M, Durmaz K. Acne and rosacea: what’s new for treatment? Dermatol Ther. 2019;32(5):e13020.PubMed
4.
Trave I, Merlo G, Cozzani E, Parodi A. Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatol Ther. 2019;32(6):e13093.PubMed
5.
Johnson SM, Berg A, Barr C. Managing Rosacea in the clinic: from pathophysiology to treatment—a review of the literature. J Clin Aesth Dermatol. 2020;13(4 Suppl):S17-S22.
6.
Rainer BM, Thompson KG, Antonescu C, et al. Characterization and analysis of the skin microbiota in Rosacea: a case-control study. Am J Clin Dermatol. 2020;21(1):139–47.PubMed
7.
Powell FC. Clinical practice. Rosacea. N Engl J Med. 2005;352(8):793–803.
8.
Ahn CS, Huang WW. Rosacea pathogenesis. Dermatol Clin. 2018;36(2):81–6.PubMed
9.
Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–7.PubMed
10.
Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78(1):148–55.PubMed
11.
Wang YA, James WD. Update on rosacea classification and its controversies. Cutis. 2019;104(1):70–3.PubMed
12.
Thyssen JP. Subtyping, phenotyping or endotyping rosacea: how can we improve disease understanding and patient care? Br J Dermatol. 2018;179(3):551–2.PubMed
13.
Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for Rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501–10.
14.
Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. Br J Dermatol. 2020;182(5):1269–76.PubMed
15.
Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017;31(11):1775–91.PubMed
16.
Asai Y, Tan J, Baibergenova A, et al. Canadian clinical practice guidelines for Rosacea. J Cutan Med Surg. 2016;20(5):432–45.PubMed
17.
Schaller M, Kemény L, Havlickova B, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82(2):336–43.PubMed
18.
Gold LS, Del Rosso JQ, Kircik L, et al. Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials. J Am Acad Dermatol. 2020;82(5):1166–73.
19.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181(1):65–79.PubMedPubMedCentral
20.
Le Cleach L, Cribier B. New evidence but still unmet medical needs in rosacea treatment. Br J Dermatol. 2019;181(1):11–2.PubMed
21.
22.
23.
Diczig B, Németh I, Sárdy M, Pónyai G. Contact hypersensitivity in rosacea—a report on 143 cases. J Eur Acad Dermatol Venereol. 2018;32(9):e347–9.PubMed
24.
Draelos ZD, Gunt H, Levy SB. Natural skin care products as adjunctive to prescription therapy in moderate to severe Rosacea. J Drugs Dermatol. 2019;18(2):141–6.PubMed
25.
Kresken J, Kindl U, Wigger-Alberti W, Clanner-Engelshofen BM, Reinholz M. Dermocosmetics for use in Rosacea: guideline of the Society for Dermopharmacy. Skin Pharmacol Physiol. 2018;31(3):147–54.PubMed
26.
27.
Baldwin H, Santoro F, Lachmann N, Teissedre S. A novel moisturizer with high sun protection factor improves cutaneous barrier function and the visible appearance of rosacea-prone skin. J Cosmetic Dermatol. 2019;18(6):1686–92.
28.
Santoro F, Lachmann N. An open-label, intra-individual study to evaluate a regimen of three cosmetic products combined with medical treatment of Rosacea: cutaneous tolerability and effect on hydration. Dermatol Ther. 2019;9(4):775–84.
29.
Husein-ElAhmed H, Steinhoff M. Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: a systematic review and meta-analysis. Dermatol Ther. 2020;33(1):e13203.PubMed
30.
Shemer A, Shiri J, Mashiah J, Farhi R, Gupta AK. Topical minocycline foam for moderate to severe acne vulgaris: phase 2 randomized double-blind, vehicle-controlled study results. J Am Acad Dermatol. 2016;74(6):1251–2.PubMed
31.
32.
Zhao YE, Wu LP, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. Arch Dermatol. 2010;146(8):896–902.PubMed
33.
Jacob S, VanDaele MA, Brown JN. Treatment of Demodex-associated inflammatory skin conditions: a systematic review. Dermatol Ther. 2019;32(6):e13103.PubMed
34.
Forton FMN, De Maertelaer V. Effectiveness of benzyl benzoate treatment on clinical symptoms and Demodex density over time in patients with rosacea and demodicosis: a real life retrospective follow-up study comparing low- and high-dose regimens. J Dermatol Treat. 2020:1–10.
35.
Forton FMN, De Maertelaer V. Treatment of rosacea and demodicosis with benzyl benzoate: effects of different doses on Demodex density and clinical symptoms. J Eur Acad Dermatol Venereol. 2020;34(2):365–9.PubMed
36.
Sheu SL. Treatment of melasma using tranexamic acid: what’s known and what’s next. Cutis. 2018;101(2):E7–8.PubMed
37.
Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. Oral tranexamic acid for the treatment of melasma: a review. Dermatol Surg. 2018;44(6):814–25.PubMed
38.
Li Y, Xie H, Deng Z, et al. Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis. Int Immunopharmacol. 2019;67:326–34.PubMed
39.
Kim MS, Chang SE, Haw S, Bak H, Kim YJ, Lee MW. Tranexamic acid solution soaking is an excellent approach for rosacea patients: a preliminary observation in six patients. J Dermatol. 2013;40(1):70–1.PubMed
40.
Bageorgou F, Vasalou V, Tzanetakou V, Kontochristopoulos G. The new therapeutic choice of tranexamic acid solution in treatment of erythematotelangiectatic rosacea. J Cosmetic Dermatol. 2019;18(2):563–7.
41.
42.
Chen L, Tsai TF. The role of β-blockers in dermatological treatment: a review. J Eur Acad Dermatol Venereol. 2018;32(3):363–71.PubMed
43.
44.
Prabha N, Chhabra N, Arora R. Beta-blockers in dermatology. Indian J Dermatol Venereol Leprol. 2017;83(3):399–407.PubMed
45.
Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatol Treat. 2018;29(3):310–3.
46.
Li J, Yuan X, Tang Y, et al. Hydroxychloroquine is a novel therapeutic approach for rosacea. Int Immunopharmacol. 2020;79:106178.PubMed
47.
48.
Kim BY, Moon HR, Ryu HJ. Comparative efficacy of short-pulsed intense pulsed light and pulsed dye laser to treat rosacea. J Cosmetic Laser Ther. 2019;21(5):291–6.
49.
Zhang Y, Jiang S, Lu Y, et al. A decade retrospective study of light/laser devices in treating nasal rosacea. J Dermatol Treat. 2020;31(1):84–90.
50.
Kapicioglu Y, Sarac G, Cenk H. Treatment of erythematotelangiectatic rosacea, facial erythema, and facial telangiectasia with a 577-nm pro-yellow laser: a case series. Lasers Med Sci. 2019;34(1):93–8.PubMed
51.
Baglieri F, Scuderi G. Treatment of recalcitrant granulomatous rosacea with ALA-PDT: report of a case. Indian J Dermatol Venereol Leprol. 2011;77(4):536.PubMed
52.
Sun Y, Chen L, Zhang Y, Gao X, Wu Y, Chen H. Topical photodynamic therapy with 5-aminolevulinic acid in Chinese patients with Rosacea. J Cosmetic Laser Ther. 2019;21(4):196–200.
53.
Fan L, Yin R, Lan T, Hamblin MR. Photodynamic therapy for rosacea in Chinese patients. Photodiagn Photodyn Ther. 2018;24:82–7.
54.
55.
Suggs AK, Macri A, Richmond H, Munavalli G, Friedman PM. Treatment of erythematotelangiectatic Rosacea with pulsed-dye laser and oxymetazoline 1.0% cream: a retrospective study. Lasers Surg Med. 2020;52(1):38–43.
56.
Deaver Peterson J, Katz TM. Open-label study assessing the efficacy and tolerability of topical skin care and sun protection alone and in combination with intense pulsed light therapy. J Cosmetic Dermatol. 2019;18(6):1758–64.
57.
Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg. 2019;45(9):1155–62.PubMed
58.
59.
60.
Amir Ali A, Vender R, Vender R. The role of IL-17 in papulopustular Rosacea and future directions. J Cutan Med Surg. 2019;23(6):635–41.PubMed
61.
62.
63.
64.
Waszczykowska A, Żyro D, Jurowski P, Ochocki J. Effect of treatment with silver(I) complex of metronidazole on ocular rosacea: design and formulation of new silver drug with potent antimicrobial activity. J Trace Elem Med Biol. 2020;61:126531.PubMed
65.
Donmez O, Akova YA. Pediatric ocular acne Rosacea: clinical features and long term follow-up of sixteen cases. Ocular Immunol Inflamm. 2019:1–9.
66.
Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465–71.PubMed
67.
68.
Schmitz L, Hessam S, Scholl L, Reitenbach S, Segert MH, Bechara FG. Wound care with a porcine extracellular matrix after surgical treatment of rhinophyma. J Cutan Med Surg. 2020;24(3):253–8.PubMed
69.
Walsh RK, Endicott AA, Shinkai K. Diagnosis and treatment of Rosacea fulminans: a comprehensive review. Am J Clin Dermatol. 2018;19(1):79–86.PubMed
70.
Nowak M, Barańska-Rybak W, Mehrholz D, Nowicki J. Rosacea fulminans—coincidence of the disease with inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2019;33(6):e247–8.PubMed
71.
Garayar Cantero M, Garabito Solovera E, Aguado García Á, Valtueña J, Ruiz Sánchez D, Manchado LP. Use of permethrin in the treatment of rosacea fulminans during pregnancy: one case report. Dermatol Ther. 2020;33(3):e13436.PubMed
72.
Merlo G, Cozzani E, Russo R, Parodi A. Dapsone for unresponsive granulomatous Rosacea. Am J Ther. 2020;27(3):e304–6.PubMed
73.
Liu RC, Makhija M, Wong XL, Sebaratnam DF. Treatment of granulomatous rosacea with chromophore gel-assisted phototherapy. Photodermatol Photoimmunol Photomed. 2019;35(4):280–1.PubMedPubMedCentral
74.
Ansorge C, Technau-Hafsi K. Granulomatous rosacea in a lung transplant recipient: A possible therapy option in a unique group of patients. Hautarzt. 2020;71(2):134–8. [Article in German].
75.
Kok WL, Oon HH, Giam YC. A case report of granulomatous rosacea of the face. Singap Med J. 2018;59(4):228–9.
76.
Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update. J Am Acad Dermatol. 2018;78(4):786–92.e8.PubMed
77.
78.
Wollina U. Is rosacea a systemic disease? Clin Dermatol. 2019;37(6):629–35.PubMed
79.
80.
Thompson KG, Rainer BM, Kang S, Chien AL. The skin microbiota as a link between rosacea and its systemic comorbidities. Int J Dermatol. 2020;59(4):513–4.PubMed
81.
Li Y, Guo L, Hao D, Li X, Wang Y, Jiang X. Association between Rosacea and cardiovascular diseases and related risk factors: a systematic review and meta-analysis. Biomed Res Int. 2020;2020:7015249.PubMedPubMedCentral
82.
Kallis PJ, Price A, Dosal JR, Nichols AJ, Keri J. A biologically based approach to acne and Rosacea. J Drugs Dermatol. 2018;17(6):611–7.PubMed
83.
Bilgin B, Karadag AS. Effects of combined oral doxycycline and topical cyclosporine treatment on ocular signs, symptoms, and tear film parameters in rosacea patients. Arquivos Brasil Oftalmol. 2018;81(6):466–70.
84.
Ebneyamin E, Mansouri P, Rajabi M, Qomi M, Asgharian R, Azizian Z. The efficacy and safety of permethrin 2.5% with tea tree oil gel on rosacea treatment: a double-blind, controlled clinical trial. J Cosmetic Dermatol. 2020;19(6):1426–31.
85.
Kwon HH, Jung JY, Lee WY, Bae Y, Park GH. Combined treatment of recalcitrant papulopustular rosacea involving pulsed dye laser and fractional microneedling radiofrequency with low-dose isotretinoin. J Cosmetic Dermatol. 2020;19(1):105–11.
86.
Lev-Tov H, Rill JS, Liu G, Kirby JS. Trends in utilization of topical medications for treatment of rosacea in the United States (2005–2014): a cohort analysis. J Am Acad Dermatol. 2019;80(4):1135–7.PubMed
87.
Kulkarni NN, Takahashi T, Sanford JA, et al. Innate immune dysfunction in rosacea promotes photosensitivity and vascular adhesion molecule expression. J Invest Dermatol. 2020;140(3):645-55.e6.PubMed
88.
Altunisik N, Turkmen D, Sener S. Investigation of the relationship between inflammatory blood parameters and rosacea and demodex infestation. J Cosmetic Dermatol. 2020;19(8):2105–8.
89.
Aldrich N, Gerstenblith M, Fu P, et al. Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol. 2015;151(11):1213–9.PubMed
90.
Mc Aleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144(6):663–71.PubMed
91.
Incel Uysal P, Akdogan N, Hayran Y, Oktem A, Yalcin B. Rosacea associated with increased risk of generalized anxiety disorder: a case-control study of prevalence and risk of anxiety in patients with rosacea. An Bras Dermatol. 2019;94(6):704–9.PubMedPubMedCentral
92.
Elewski B. Rosacea treatment: a patient-centric approach. Br J Dermatol. 2020;182(5):1090–1.PubMed
93.
Cices A, Alexis AF. Patient-focused solutions in Rosacea management: treatment challenges in special patient groups. J Drugs Dermatol. 2019;18(7):608–12.PubMed
94.
Tan J, Berg M, Gallo RL, Del Rosso JQ. Applying the phenotype approach for rosacea to practice and research. Br J Dermatol. 2018;179(3):741–6.PubMed
95.
Diamantis S, Waldorf HA. Rosacea: clinical presentation and pathophysiology. J Drugs Dermatol. 2006;5(1):8–12.PubMed
Metadata
Title
Rosacea Treatment: Review and Update
Authors
Hanlin Zhang
Keyun Tang
Yuchen Wang
Rouyu Fang
Qiuning Sun
Publication date
01-02-2021
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2021
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-020-00461-0

Other articles of this Issue 1/2021

Dermatology and Therapy 1/2021 Go to the issue

Review

Gut–Brain–Skin Axis in Psoriasis: A Review

Original Research

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

Original Research

Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?

Brief Report

Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia

Review

New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review

Original Research

Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits